Its latest deal is with the Japanese group Tenshindo, a manufacturer of functional foods and cosmetics, which has signed a licence agreement for the UK group’s Lactobacillus plantarum (LPLDL) bacteria strain.
The idea is to incorporate LPLDL into heart-healthy food supplements, while the pair are aiming to obtain an authorised cardiovascular claim for the OptiBiotix technology.
Gaining validation of this kind, which would be based on existing clinical and market evidence, would be “highly advantageous from the commercial point of view, but also an important endorsement for [the] science”, said Dr Luis Gosalbez, business development director of OptiBiotix.
Latest of series of deals
The tie-up for the AIM-listed firm’s ProBiotix Health division is the latest in a series of commercial agreements.
Earlier this week it teamed with Kappa Biosciences of Norway to create a new vascular health product in Europe.
Meanwhile, last month it named a partner to bring its weight management technology to North America.
OptiBiotix’s compounds have been created to tackle obesity, cardiovascular disease and diabetes.
And, as mentioned above, they are focused on the human microbiome, an ecosystem of bacteria found in the gut or on the skin.